ライフサイエンスコーパス: persistent pulmonary hypertension

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 g adjunct to inhaled NO for the treatment of persistent pulmonary hypertension.

2 e decreases severe hypoxemia in infants with persistent pulmonary hypertension.

3 ate or severe right ventricular hypokinesis, persistent pulmonary hypertension, a patent foramen oval

4 oembolic pulmonary hypertension (CTEPH), but persistent pulmonary hypertension after PTE, as a result

5 mproves systemic oxygenation in infants with persistent pulmonary hypertension and may reduce the nee

6 ysis may identify CTEPH patients at risk for persistent pulmonary hypertension and poor outcome after

7 ed to the underlying disease associated with persistent pulmonary hypertension and that lung recruitm

8 borns with hypoxemic respiratory failure and persistent pulmonary hypertension, and is now a standard

9 ates with hypoxaemic respiratory failure and persistent pulmonary hypertension, but potential adverse

10 neonates transferred for rescue therapy for persistent pulmonary hypertension during the study perio

11 Infants with persistent pulmonary hypertension have low plasma concen

12 rginine would correlate with the presence of persistent pulmonary hypertension in newborns and that t

13 psis, septicemia, septic shock, endotoxemia, persistent pulmonary hypertension, nitric oxide, and ext

14 psis, septicemia, septic shock, endotoxemia, persistent pulmonary hypertension, nitric oxide, extraco

15 nitric oxide bioactivity in the treatment of persistent pulmonary hypertension of newborns.

16 idepressant use during pregnancy and risk of persistent pulmonary hypertension of the newborn (PPHN)

17 Severe persistent pulmonary hypertension of the newborn (PPHN)

18 The main change was to withdraw persistent pulmonary hypertension of the newborn (PPHN)

19 Infants with persistent pulmonary hypertension of the newborn (PPHN)

20 Persistent pulmonary hypertension of the newborn (PPHN)

21 nary vascular resistance after birth, and in persistent pulmonary hypertension of the newborn (PPHN),

22 e serotonin reuptake inhibitors (SSRIs) with persistent pulmonary hypertension of the newborn (PPHN),

23 nation and clinical outcomes in infants with persistent pulmonary hypertension of the newborn and ass

24 ness of inhaled NO treatment in infants with persistent pulmonary hypertension of the newborn and ass

25 Persistent pulmonary hypertension of the newborn causes

26 Persistent pulmonary hypertension of the newborn is char

27 ression may increase levels of superoxide in persistent pulmonary hypertension of the newborn lung ti

28 Eleven neonates with severe persistent pulmonary hypertension of the newborn receivi

29 ation (ECMO) use or death among infants with persistent pulmonary hypertension of the newborn who rec

30 anomalies, neonatal withdrawal syndrome, and persistent pulmonary hypertension of the newborn.

31 borns with hypoxemic respiratory failure and persistent pulmonary hypertension of the newborn.

32 ions, except for one single-center trial for persistent pulmonary hypertension of the newborn.

33 reliable in identifying patients at risk for persistent pulmonary hypertension or predicting postoper

34 ation fetal lambs, and in newborn lambs with persistent pulmonary hypertension (PPHN) after prenatal

35 led nitric oxide (iNO) in newborn lambs with persistent pulmonary hypertension (PPHN) following prena

36 tion appears to be decreased in infants with persistent pulmonary hypertension (PPHN).

37 In neonates with persistent pulmonary hypertension, therapy with inhaled

38 full-term infants with severe hypoxemia and persistent pulmonary hypertension were randomly assigned

39 Infection in many cases causes persistent pulmonary hypertension, which impairs gas exc

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。